Viridian Therapeutics
VRDN · NASDAQ
$22.43+$1.63 (+7.84%)TodayMarket closed ·
Prev close $20.80
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 18.3% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- -$1.04
- Revenue estimate
- $4.89M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$1.05 | -$1.05 | −0.0% |
| Q1 FY26 | -$1.12 | -$0.90 | +19.4% |
| Q4 FY25 | -$1.09 | -$1.08 | +1.0% |
| Q3 FY25 | -$1.10 | -$0.34 | +69.2% |
| Q2 FY25 | -$1.03 | -$1.00 | +2.9% |
| Q1 FY25 | -$0.9864 | -$0.87 | +11.8% |
| Q4 FY24 | -$1.06 | -$1.00 | +5.3% |
| Q3 FY24 | -$1.08 | -$1.15 | −6.6% |
Earnings calls
- Special Call - Viridian Therapeutics, Inc.
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Special Call - Viridian Therapeutics, Inc.
- Special Call - Viridian Therapeutics, Inc.
- Goldman Sachs 46th Annual Global Healthcare Conference 2025
- Special Call - Viridian Therapeutics, Inc.
- Special Call - Viridian Therapeutics, Inc.
- Goldman Sachs 45th Annual Global Healthcare Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.